instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
"We don’t know yet if the Ebola scare will help either party or be an afterthought in the midterm elections, but liberal blogger Doug Muder argued that confronting Ebola shows that it makes sense to vote Democratic. For Muder, Kentucky Republican Sen. Rand Paul is the poster child for a distinct partisan contrast. ""Ebola points out why we need a fully funded government,"" Muder wrote. ""When there’s no immediate threat of disease, government agencies like the CDC look like bureaucratic waste. When Rand Paul put out a ‘Tea Party budget’ in 2011, it included a big cut in the CDC, and virtually no explanation as to how this would affect its mission."" In this fact-check, we look at whether Paul proposed a ""big cut"" in the Centers for Disease Control and Prevention. Muder had blogged about Paul’s budget in 2011. Back then, Muder asked how the CDC would be able to fulfill its mission if, as Paul wanted, its budget was cut by $1.165 billion. We went back to Paul’s original budget documents. One posted January 2011 called for the $1.165 billion reduction that Muder mentioned. Paul then assembled a more complete budget plan in May 2011. It would cut the CDC budget by 20 percent from its Fiscal Year 2008 levels. Depending on whether you include special funds to evaluate federal health programs, Congress appropriated between $6.049 billion and $6.375 billion for the CDC in FY 2008. So Rand’s 20 percent reduction amounts to either $1.209 billion or $1.275 billion in cuts. That’s slightly more than Muder described. Paul wrote in his plan, ""The center is often mentioned in media reports highlighting their lavish accommodations. For example, in 2005, the CDC built a conference center for $106 million, complete with large-screen plasma TVs. They also spent tens of millions of dollars on state-of-the-art anti-gravity seating for employees, as well as luxury furniture. Taxpayers can no longer afford the luxury working atmosphere of the CDC."" That budget plan remains posted on the website randpaul2016.com, Paul's Senate re-election website. Brian Darling, a Paul spokesman, agreed that the senator has proposed these cuts in the past, but said that funding and the ability to fight Ebola don’t inevitably go hand-in-hand. ""If you look closely at the CDC budget, there are funds that have been wasted on projects that have nothing to do with disease prevention,"" Darling said. Darling then noted that Congress has been at least as supportive of the CDC as the Obama administration. Darling said that in an omnibus spending bill, Congress appropriated $6.9 billion for the CDC, about $240 million more than the administration requested. Darling highlighted another $88 million for Ebola in a continuing resolution bill approved in September. However, neither action undercuts Muder’s point, and Paul voted against both measures. It’s important to remember that those bills doled out money across many government agencies, not specifically for the CDC alone. Sometimes reasonable people can quibble over whether a cut is ""big"" or not. In this case, Paul himself called his cuts ""serious"" in a 2011 op-ed he penned for the Wall Street Journal. ""My proposal, not surprisingly, has been greeted skeptically in Washington, where serious spending cuts are a rarity,"" Paul wrote. ""But it is a modest proposal when measured against the size of our mounting debt."" Our ruling Muder said that in 2011 Sen. Paul proposed cutting the CDC budget by $1.165 billion. Budget documents confirm that. In fact, Paul’s most detailed budget that year would have trimmed CDC spending by slightly more, about $1.2 billion. While the Senate approved two broad spending measures to fund the CDC in 2014, Paul voted against both."
answer:
"Doug Muder Says Sen. Rand Paul’s 2011 budget ""included a big cut in the CDC."


question:
The news release does not mention costs. While a new therapy may not have an established price, the release could have stated “no price is available for this drug.” What would be even better is some context for what women suffering from postpartum pay typically for counseling and medications. The release notes that  there was a reduction in depressive symptoms of 17 points for those on the drug, and 12.8 for those in the placebo group based on the Hamilton Depression Rating Scale. The absolute reduction in the rating scale is given for each group. This information would have been much more helpful if the release also clarified the magnitude of the scale and whether a 4.2-point difference is clinically meaningful. The release contains one somewhat vague sentence on harms. The most common (≥10% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence. Readers would also be interested in details on whether the drug is safe for nursing infants. That’s not mentioned. The double-blinded randomized trials are described in detail and readers are able to judge the quality of the evidence. The published study includes an important limitation of the research that’s not mentioned in the release: The trials assessed women for only 30 days; the effects of the treatment beyond 30 days are “unknown.” There is no disease mongering. The release explains how common postpartum depression is worldwide. The release notes that Sage Therapeutics funded the research. Sage Therapeutics is the developer of brexanolone injection and sponsor of the trials. A New Drug Application is currently under review by the FDA and brexanolone injection has been granted Breakthrough Therapy Designation. The FDA has assigned a Prescription Drug User Fee Act target date of December 19, 2018. What the release doesn’t tell us is that both quoted researchers disclosed financial ties with Sage Therapeutics. This information was included in the studies published in the Lancet. SM-B reports personal fees from MedScape and grants from Sage Therapeutics, awarded to the University of North Carolina … DRR reports personal fees and has stock options in Sage Therapeutics…. The release mentions that women currently can receive antidepressants for postpartum depression, but that the new drug being studied goes to work relieving symptoms faster than traditional antidepressants — days rather than weeks. The release notes that the drug is currently under FDA review, with a decision on its approval expected by the end of the year. The release notes that the new drug would be a novel treatment for postpartum depression, if approved. There is no unjustifiable language.
answer:
Newly Published Results Show Investigational Treatment Brexanolone Consistently Reduced Depressive Symptoms Across Three Postpartum Depression Trials, Supporting Submission for FDA Approval


question:
Although the story mentions the high upfront cost of proton therapy, it does not describe the cost of treatment compared to other alternatives. The story points out that there have been no controlled treatment trials for proton therapy in prostate cancer–increasingly the targeted use–so there really are no good data on benefits. Since the technology is relatively new there are probably no good long-term survival estimates even from case series. The story mentions side effects of proton therapy, such as incontinence and sexual side effects in men with prostate cancer, and explains that they may be more common than reported in studies. The story mentions that there is a lack of randomized trials comparing proton therapy to conventional radiation. The story does not appear to engage in disease mongering. However, the article doesn’t indicate that many of the 186,320 new prostate cancer cases are early-stage for which the benefit of any treatment–let alone proton beam–remains uncertain. The story quotes multiple experts who provide meaningful perspectives on the value of proton therapy. The story mentions conventional radiation and surgery as the alternatives to proton therapy. The story accurately describes the limited availability of proton therapy. The story accurately describes the novelty of proton therapy. Because the story quotes multiple experts, the reader can assume that the story does not rely on a press release as the sole source of information.
answer:

The promise of proton-beam therapy